JP2013511526A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511526A5
JP2013511526A5 JP2012539987A JP2012539987A JP2013511526A5 JP 2013511526 A5 JP2013511526 A5 JP 2013511526A5 JP 2012539987 A JP2012539987 A JP 2012539987A JP 2012539987 A JP2012539987 A JP 2012539987A JP 2013511526 A5 JP2013511526 A5 JP 2013511526A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
agent
substituted
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012539987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511526A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056942 external-priority patent/WO2011062939A1/en
Publication of JP2013511526A publication Critical patent/JP2013511526A/ja
Publication of JP2013511526A5 publication Critical patent/JP2013511526A5/ja
Ceased legal-status Critical Current

Links

JP2012539987A 2009-11-18 2010-11-17 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物 Ceased JP2013511526A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26234209P 2009-11-18 2009-11-18
US61/262,342 2009-11-18
US29203210P 2010-01-04 2010-01-04
US61/292,032 2010-01-04
PCT/US2010/056942 WO2011062939A1 (en) 2009-11-18 2010-11-17 Methods and compositions for treating solid tumors and other malignancies

Publications (2)

Publication Number Publication Date
JP2013511526A JP2013511526A (ja) 2013-04-04
JP2013511526A5 true JP2013511526A5 (enExample) 2015-06-11

Family

ID=43384585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539987A Ceased JP2013511526A (ja) 2009-11-18 2010-11-17 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物

Country Status (18)

Country Link
US (2) US20120232087A1 (enExample)
EP (1) EP2501370A1 (enExample)
JP (1) JP2013511526A (enExample)
KR (1) KR20120107962A (enExample)
CN (2) CN102665700A (enExample)
AU (1) AU2010322114B2 (enExample)
BR (1) BR112012011823A2 (enExample)
CA (1) CA2781210A1 (enExample)
CL (1) CL2012001271A1 (enExample)
IL (1) IL219636A0 (enExample)
MA (1) MA33739B1 (enExample)
MX (1) MX2012005695A (enExample)
NZ (1) NZ599964A (enExample)
PH (1) PH12012500911A1 (enExample)
RU (1) RU2012125152A (enExample)
TN (1) TN2012000205A1 (enExample)
WO (1) WO2011062939A1 (enExample)
ZA (1) ZA201203325B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2501236B1 (en) 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
EP2715366B1 (en) * 2011-06-02 2017-07-19 Novartis AG Biomarkers for hedgehog inhibitor therapy
WO2013106812A1 (en) * 2012-01-12 2013-07-18 Board Of Regents, The University Of Texas System Personalized medicine for the prediction of therapy targeting the hedgehog pathway
JP6293770B2 (ja) * 2012-11-05 2018-03-14 ナント ホールディングス アイピー,エルエルシー ヘッジホッグシグナル伝達経路阻害剤としての環状スルホンアミド含有誘導体
CN103524535B (zh) * 2013-10-16 2016-07-13 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
KR20200125758A (ko) 2017-10-27 2020-11-04 베링거 인겔하임 인터내셔날 게엠베하 피리딘 카보닐 유도체 및 trpc6 억제제로서 이의 치료학적 용도
EP3817743A4 (en) * 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
KR101464384B1 (ko) 2005-11-22 2014-11-21 쿠도스 파마슈티칼스 리미티드 mTOR 억제제로서 피리도피리미딘, 피라조피리미딘 및피리미도피리미딘 유도체
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
JP5227321B2 (ja) 2006-08-23 2013-07-03 クドス ファーマシューティカルズ リミテッド Mtor阻害剤としての2−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
US8536168B2 (en) * 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
ES2569941T3 (es) * 2007-06-07 2016-05-13 Novartis Ag Derivados de bifenilcarboxamida como moduladores de la ruta de hedgehog
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009112266A1 (en) * 2008-03-12 2009-09-17 Ludwig-Maximilians-Universität Active substance combination with gemcitabine for the treatment of epithelial cancer
CN102066353B (zh) * 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors

Similar Documents

Publication Publication Date Title
ES2609767T3 (es) Combinaciones de un inhibidor de PI3K y un inhibidor de MEK
Nonnenmacher et al. RIST: A potent new combination therapy for glioblastoma
RU2508110C2 (ru) КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
JP6648040B2 (ja) がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
JP5579715B2 (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
AU2015289504B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
ES2861180T3 (es) Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etan-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
TW202446772A (zh) Sting促效化合物
JP2022145800A (ja) 静止細胞標的化およびegfr阻害剤を用いた新生物の処置のための組み合わせ
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
JP2018510869A (ja) 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリンを含んでいる組合せ
AU2013341271A1 (en) Combination therapy
JP5440985B2 (ja) メラノーマの治療
JP2020523354A5 (enExample)
JP2013511526A (ja) 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物
ES2685974T3 (es) Derivados de cefalosporina para tratar el cáncer
CA3253034A1 (en) METHODS FOR TREATMENT OF MYELOID MALIGNITIS USING A BCL-2 INHIBITOR
MX2023011814A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer.
ITMI20042475A1 (it) Uso di derivati tiazolidinonici come agenti terapeutici
CN112237579A (zh) 药物组合及其用途
CN102105148B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
Kasper et al. Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?
RU2012123970A (ru) Тивозаниб и темсиролимус в комбинации
RU2009128186A (ru) Производные трициклических аминов в качестве ингибиторов тирозинкиназы
JP2013510899A5 (enExample)